Discovery of podophyllotoxins

Biochimie

Volumn 80, Issue 3, 1998, Pages 207-222

  Imbert, T F ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Etoposide; Podophyllotoxin; Teniposide; Topoisomerase; Tubulin

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; ALPHA PELTATIN; ANTINEOPLASTIC AGENT; AZATOXIN; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOFOS; ETOPOSIDE; GL 331; GYRASE INHIBITOR; LIGNAN DERIVATIVE; PODOPHYLLOTOXIN; TENIPOSIDE; TOP 53; TUBULIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; DRUG ISOLATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; MICROTUBULE ASSEMBLY; REVIEW;

EID: 0032033637     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(98)80004-7     Document Type: Article

References (154)

1. 1 Horwitz SB, Loike JD (1977) A comparison of the mechanism of action of VP-16-213 and Podophyllotoxin. J Natl Prod 40, 82-89
2. 2 Kelly MG, Hartwell JL (1954) The biological effects and the chemical composition of podophyllin. A review. J Natl Cancer Inst 14, 967-1010
3. 3 Jardine I (1980) Podophyllotoxins. Anticancer Agents Based on Natural Product Models. Academic Press, New-York, 16, 319-351
4. 4 Hartwell JL, Schrecker AW (1958) The chemistry of podophyllin. Fortschr Chem Org Naturst 15, 83
5. 5 Stähelin H, von Wartburg A (1989) From podophyllotoxin glucoside to etoposide. Prog Drug Res 33, 169-267
6. 6 Stähelin H, von Wartburg A (1991) The chemical and biological route from Podophyllotoxin to etoposide. Cancer Res 51, 5-15
7. 7 Von Wartburg A, Stähelin H (1993) Etoposide. Chronicle of Drug Discovery (Lednicer D, ed) ACS Washington DC, 3, 349-380
8. 8 Catersby M (1731) In: Natural History of Carolina, Florida, and the Bahamas Islands. Tome I, 24
9. 9 Moermann DE (1986) Medicinal plant of native America. University of Michigan, Museum of anthropology, technical report No 19, Ann Arbor
10. 10 Lombard LH (1952) Medicinal plants of our Maine Indians. In: The Maine writers research club. Maine Indians in history and legends (Severn-Wylie-Jewel, eds), Portland
11. 11 Brunet O (1865) Catalogue des Plantes Canadiennes Contenues dans l'Herbier de l'Université Laval, Québec, 15-16
12. 12 Fenton WN (1941) Contacts between Iroquois herbalism and colonial medecine. Smithsonian Report Washinton DC, Pub 3670
13. 13 Buchan W (1772) Domestic Medicare, London (Lloyd Library,Cincinnati)
14. 14 Bentley R (1861) The American Remedies. Podophyllum peltatum. Pharm J Trans 3, 456-464
15. 15 Dorvault (1884) L'officine ou Répertoire Général de Pharmacie Pratique. Labé, Libr Fac Med 352
16. 16 Codex Medicamentarius Gallicus (1937) Pharmacopée française, 6th edn, Impr Oberthur, Rennes
17. 17 Chatterjee R (1952) Indian Podophyllum. Economic Botany 6, 342-354
18. 18 Wallich N (1929) A numerical list of dried plants in the East India Company's Museum. (Wallich's Catalogue) London
19. 19 Royle JF (1839) Illustration of the botany and other branches of natural history of the himalayan mountains and the flora of Cashmere (WC Allen & Co, eds), London
20. 20 Jackson DE, Dewick PM (1985) Tumour inhibitory aryltetralin lignans from Podophyllum pleianthum. Phytochemistry 24, 2407-2409
21. 21 Soejarto DD, Faden RB, Farnsworth NR (1979) Indian Podophyllum is it Podophyllum emodi or Podophyllum hexandrum? Taxon 28, 549-551
22. 22 Dymock W (1972) Pharmacographica Indica. Hamdart Foundation, Karachi
23. 23 Pettit GR (1977-1979) Biosynthetic products for Cancer Chemotherapy. Vol 1-3 Plenum, New York
24. 24 Akahori A, Yasuda F, Ando M, Hori K, Okanishi K (1972) Cytotoxic agents of Thujopsis dolabrata (L fil) Sieb and Zucc. Chem Pharm Bull 20, 1150-1155
25. 25 Weiss SG, Tin-Wa M, Perdue R E Jr, Farnworth NR (1975) Potential and cancer agents II. Antitumor and cytotoxic lignans from Linum album (Linaceae). J Pharm Sci 64, 95-98
26. 26 Hoffmann JJ, Weidhopf RM, Cole JR (1977) Cytotoxic and tumor inhibitory agent from Polygala macradenia Gray. J Pharm Sci 66, 586-587
27. 27 Hokanson GC (1978) Podophyllotoxin and 4′-demethylpodophyllotoxin from Polygala polygama (Polygalaceae). Lloydia 41, 497-498
28. 28 Kamil WM, Dewick PM (1986) Biosynthetic relationship of aryltetralinlactone lignanes to dibenzylbutyrolactone lignans. Phytochemistry 25, 2093-2102
29. 29 Ayres DC, Farrow A, Carpenter BG (1981) Lignans and related phenols. Part 16. The biogenesis of podophyllotoxin. J Chem Soc Perkin Trans I, 2134-2136
30. 30 Jackson DE, Dewick PM (1984) Biosynthesis of Podophyllum lignans I. Cinnamic acid precursors of podophyllotoxin in Podophyllum hexandrum. Phytochemistry 23, 1029-1035
31. 31 Jackson DE, Dewick PM (1984) Biosynthesis of Podophyllum lignans II. Interconversions of aryltetralin lignans in Podophyllum hexandrum. Phytochemistry 23, 1037-1042
32. 32 Damon RE, Schlessinger RH, Blount JF (1976) A short synthesis of isostegnane. J Org Chem 41, 3772-3773
33. 33 Kupchan SM, Britton RW, Ziegler MF, Gilmore CJ, Restivo RJ, Bryan RF (1973) Steganacin and steganangin, novel antileukemic lagnan lactones from Steganotaenia araliaceae. J Am Chem Soc 95, 1335-1336
34. 34 Sackett DL (1993) Podophyllotoxin, Steganacin and Combretastatin: natural products that bind at the colchicine site of tubulin. Pharmacol Ther 59, 163-228
35. 35 Kutney JP (1993) Plant cell culture combined with chemistry: a powerfull route to complex natural products. Acc Chem Res 26, 559-566
36. 36 King J (1844) New York Philosophical MJ, 1, 159-161
37. 37 King J (1846) West M Reformer, 5, 175-178
38. 38 King J (1854) The American Eclectic Dispensatory. Cincinnati, Moore, Wilstack, and Keys, 746-754
39. 39 King J (1857) Discovery of Podophyllin. Coll J M Sci 2, 557-559
40. 40 Lloyd JU (1910) The eclectic alkaloids: Bull Lloyd library of botany, pharmacy and materia medica Pharmacy Ser 2, Bull 12, 7-10
41. 41 Podwyssotzki V (1881) The active constituant of podophyllin. Pharm J Trans 12, 217-218
42. 42 Podwyssotzki V (1882) On the active constituents of podophyllin. Am J Pharm 12, 102-115
43. 43 Podwyssotzki V (1884) Pharmakologische Studien über Podophyllum peltatum. Naunyn Schmied Arch Exp Path Phar 13, 29-52
44. 44 Umney JC (1892) Podophyllum emodi. Pharm J Trans 23, 207-210
45. 45 Gensler WJ, Gatsonis CD (1966) The podophyllotoxin-picropodophyllotoxin equilibrium. J Org Chem 31, 3224-3227
46. 46 Hartwell JL, Shear MJ (1947) Chemotherapy of cancer: Classes of compounds under investigation, and active components of podophyllin. Cancer Res 7, 716-717
47. 47 Borsche W, Niemann J (1932) Über Podophyllin. Liebigs Ann Chem 494, 126-142
48. 48 Späth E, Wessely F, Kornfeld L (1932) Über die konstitution von Podophyllotoxin und Pikro-podophyllin. Chem Ber 65, 1536-1549
49. 49 Späth E, Wessely F, Nadler E (1932) Zur Konstitution des Podophyllotoxins und Picro-podophyllins. Chem Ber 65, 1773-1777
50. 50 Späth E, Wessely F, Nadler E (1933) Zur Konstitution des Podophyllotoxins und Picro-podophyllins. Chem Ber 66, 125-130
51. 51 Hartwell JL, Schrecker AW (1951) Components of podophyllin. V. The constitution of podophyllotoxin. J Am Chem Soc 73, 2909-2916
52. 52 Schrecker AW, Hartwell JL (1956) Components of podophyllin. XX. The absolute configuration of podophyllotoxin and related lignans. J Org Chem 21, 381-382
53. 53 Gensler WJ, Gatsonis CD (1962) Synthesis of podophyllotoxin. J Am Chem Soc 84, 1748-1749
54. 54 Gensler WJ, Gatsonis CD (1966) Synthesis of podophyllotoxin. J Org Chem 31, 4004-4008
55. 55 Kofold H, Jorgensen C (1954) Dehydropodophyllotoxin, a new compound isolated from Podophyllum peltatum. Acta Chem Scand 8, 1296-1297
56. 56 Hutshinson J (1872) Severe ulceration of corneae caused by the dust-given off by podophyllin root whilst being ground-eruption on the skin from the same cause. M Times Gaz 2, 516
57. 57 Kürsten R (1891) Über die Bestanteile von Rhizoma Podophylli. Arch Pharm 229, 220-248
58. 58 Neuberger J (1891) Über die Wirkungen des kristallisierten Podophyllotoxins. Arch Exp Pathol Pharmakol 28, 32-40
59. 59 Kaplan IW (1942) Codylomata acuminata. New Orleans Med Surg J 94, 388
60. 60 King LS, Sullivan M (1946) The similarity of the effects of podophyllin and colchicine and their use in treatment of Condylomata acuminata. Science 104, 244-245
61. 61 Sullivan BJ, Weshler HI (1947) The cytological effects of podophyllin, Science 105, 433
62. 62 Belkin M (1947) Effects of podophyllin on transplanted mouse tumors. Fed Proc 6, 308
63. 63 Sullivan M, King LS (1947) Effect of resin of Podophyllum on normal skin, Condylomata acuminata, and Verrucae vulgares. Arch Dermat Syph 56, 30-47
64. 64 Seidlova-Masinova V, Malinsky J, Santavy F (1957) The biological effect of some podophyllotoxin compounds and their dependence on chemical structure, J Natl Cancer Inst 18, 359-369
65. 65 Wilson L, Friedkin M (1967) The biochemical events of mitosis II. The in vivo and in vitro binding of colchicine in grasshopper embryos and its possible relation to inhibition of mitosis. Biochemistry 6, 3126-3141
66. 66 Wilson L, Hamburg JR, Mizel SB, Grisham LM, Creswell KM (1974) Fed Proc Fed Am Soc Exp Biol 33, 158
67. 67 Cortese F, Bhattacharyya B, Wolf J (1977) Podophyllotoxin as a probe for the colchicine binding site of tubulin J Biol Chem 252, 1134-1140
68. 68 ter Haar E, Rosenkrantz HS, Hamel E, Day BW (1996) Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents. Bioorg Med Chem 4, 1659-1671
69. 69 Stoll A, Renz J, von Wartburg A (1954) The isolation of podophyllotoxin glucoside. J Am Chem Soc 76, 3103-3104
70. 70 Stoll A, Renz J, von Wartburg A (1954) Natural products inhibiting mitosis. II. The isolation of podophyllotoxin glucoside from Indian Podophyllum emodi. Helv Chim Acta 37, 1747-1762
71. 71 Stoll A, von Wartburg A, Angliker E, Renz J (1954) The isolation of 4′-demethylepipodophyllotoxin glucoside from rhizomes of Podophyllum emodi. J Am Chem Soc 76, 5004-5005
72. 72 Cerletti A, Emmenegger H, Stähelin H (1959) Antimitotic properties of substances derived from podophyllotoxin. Actual Pharmacol (Paris) 12, 103-128
73. 73 Emmenegger H, Stähelin H, Rutschmann J, von Wartburg A (1961) Chemistry and phararmacology of Podophyllum glucosides and derivatives. I. Arzneimittel Forsch 11, 327-333
74. 74 Kuhn M, von Wartburg A (1968) Mitosis inhibiting substances. XX. Cleavage of acyl protective groups in alkali-sensitive glucosides. Helv Chim Acta 51, 163-168
75. 75 Kuhn M, von Wartburg A (1968) Mitosis inhibiting substances. XXI. New glycosidation method. Synthesis of epipodophyllotoxin β-D-glucopyranoside Helv Chim Acta 51, 1631-1641
76. 76 Kuhn M, von Wartburg A (1969) Mitosis-inhibiting substances. Glycosidation process. II, Glycosides of 4′-demethylepipodophyllotoxin. Helv Chim Acta 52, 948-955
77. 77 Kuhn M, Keller-Juslén C (1969) Mitosis inhibiting substances. XXII. Partial synthesis of 4′-demethylepipodophyllotoxin. Helv Chim Acta 52, 944-947
78. 78 Stähelin H (1972) Chemie und Wirkungsmechanismus von Podophyllin-Derivaten. Planta Med 22, 336-347
79. 79 Keller-Juslén C, Kuhn M, von Wartburg A (1971) Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin. J Med Chem 14, 936
80. 80 Nissen N I, Larsen V, Pedersen H, Thomsen K (1972) Phase I clinical trial of a new antitumor agent 4′-demethylepipodophyllotoxin-9- (4,6-O-ethylidene-β-glucopyranoside) (NSC 141540: VP-16-213). Cancer Chemother Rep 56, 769
81. 81 Loike JD, Horwitz SB, Grollman AP (1974) Effects of VP 16-213 on HeLa cells. Pharmacologist 16, 209
82. 82 Loike JD, Horwitz SB (1976) Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 15, 5435-5443
83. 83 Loike JD, Horwitz SB (1976) Effects of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 15, 5443-5448
84. 84 Ross WE, Glaubiger DL, Kohn KW (1978) Protein-associated DNA breaks in cells treated with adriamycin and ellipticine. Biochim Biophys Acta 519, 23-30
85. 85 Ross WE, Glaubiger DL, Kohn KW (1979) Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta 562, 41-50
86. 86 Ross WE, Zwelling LA, Kown KW (1979) Relationship hetween cytotoxicity and DNA strand breakage produced by adriamycin and other intercalating agents. Int J Radiat Oncol Biol Phys 5, 1221-1224
87. 87 Loike JD, Brewer CF, Sternlicht H, Gensler WJ, Horwitz SB (1978) Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners. Cancer Res 38, 2688-2693
88. 88 Loike JD (1982) VP16-213 and Podophyllotoxin: a study on the relationship between chemical structure and biological activity. Cancer Chemother Pharmacol 7, 103-111
89. 89 Wozniak AJ, Ross WR (1983) DNA damage as a basis for 4′-demethylepipodophyllotoxin-9- (4,6-O-ethylidene-β-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res 43, 120-124
90. 90 Glisson BS, Smallwood SE, Ross WE (1984) Characterization of VP-16 induced DNA damage in isolated nuclei from L 1210 cells. Biochim Biophys Acta 783, 74
91. 91 Kalwinski DK, Look AT, Ducore J, Fridland A (1983) Effect of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res 43, 1592-1597
92. 92 Ross W, Rowe T, Glisson B, Yalowich J, Liu L (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44, 5857-5860
93. 93 Long BH, Brattain MG (1984) The activity of etoposide (VP-16-213) and teniposide (VM-26) against human lung tumor cells in vitro: cytotoxicity and DNA breakage. In: Etoposide (VP-16): current status and new developments, (Issell BF, Muggia FM, Carter SA, eds) Academic Press, New-York, 223 p
94. 94 Long BH, Minocha A (1983) Inhibition of topoisomerase II by VP-16-213 (etoposide), VM-26 (teniposide), and structured congeners as an explanation for in vivo DNA breakage and cytotoxicity. Proc Am Ass Cancer Res 24, 1271
95. 95 Long BH, Musial ST, Battrain MG (1984) Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 23, 1183-1188
96. 96 Minocha A, Long BH (1984) Inhibition of the DNA catenation activity of type II topoisomerase by VP16-213 and VM26. Biochem Biophys Res Commun 122, 165-170
97. 97 Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ, Khown KW (1987) Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells Cancer Res 47, 2050-2055
98. 98 Grieder A, Maurer R, Stähelin H (1974) Effect of an epipodophyllotoxin derivative (VP 16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro. Cancer Res 34, 1788-1793
99. 99 Nelson EM, Tewey KM, Liu LF (1984) Mechanism of antitumor drug action: Poisoning of mamalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino) methansulfon-m-anisidine. Proc Natl Acad Sci USA 81, 1361-1365
100. 100 Tewey KM, Chen GL, Nelson EM, Liu LF (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mamalian DNA topoisomerase II. J Biol Chem 259, 9182-9187
101. 101 Long BH (1987) NCI Monograph 4, 123
102. 102 Pommier Y, Kohn K (1989) Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins. In: Developments in cancer chemotherapy (Glazer RI, ed) vol II CRC Press Boca Raton, Florida, p 175
103. 103 Haim N, Nemec J, Roman J, Sinha BK (1987) Peroxidase-catalyzed metabolism of etoposide (VP-16,213) and covalent binding of reactive intermediates to cellular macromolecules. Cancer Res 47, 5835-5840
104. 104 Haim N, Roman J, Nemec J, Sinha BK (1986) Peroxidative free radical formation and O-demethylation of etoposide (VP-16) and teniposide (VM-26). Biochem Biophys Res Commun 135, 215-220
105. 105 Sinha BK, Trush MA, Kalyanaraman B (1985) Microsomal interactions and inhibition for Lipid peroxidation by etoposide (VP-16,213): implications for mode of action. Biochem Pharmacol 34, 2036-2040
106. 106 Teicher BA, Holden SA, Rose CM (1985) Effect of oxygen on the cytotoxic and antitumor activity of etoposide. J Natl Cancer Inst 75, 1129-1133
107. 107 Sinha BK, Eliot HM, Kalayanaraman B (1988) Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16. FEBS Lett 227, 240-244
108. 108 Dombernowsky P, Nissen NI, Larsen V (1972) Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4′-demethyl-9- (4,6-O-2-thenylidene-β-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep 56, 71
109. 109 Sontag RW, Sen HJ, Nage G, Giger K, Alberto P (1974) Experience with 4′-demethylepipodophyllotoxin-9- (4,6-O-2-thenylidene-β-glucopyranoside), (VM-26; NSC 122819) in the treatment of malignant lymphosis. Eur J Cancer 10, 93
110. 110 Mathé G, Schwarzenberg L, Pouillart P, Oldham R, Weiner R, Jasmin C, Rosenfeld C, Hayat M, Misset J, Musset M, Schneider M, Amiel JL, De Vassal F (1974) Two epipodophyllotoxin derivatives, VM-26 and VP-16-213 in the treatment of leukemia, hematosarcomas and lymphomas. Cancer 34, 985
111. 111 Aisner J, Wiernik PH (1980) Chemotherapy versus chemoimmunotherapy for small-cell undifferenciated carcinoma of the lung. Cancer 46, 2543-2549
112. 112 William S D, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cis-platin, bleomycin, and either vinblastine or etoposide, New Engl J Med 316, 1435-1440
113. 113 O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE (1985) Etoposide (VP-16-213). Current status of an active anticancer drug. New Engl J Med 312, 692-700
114. 114 Taylor RE, Mc Elwain TJ, Barren A, Peckham MJ (1982) Etoposide as a single agent in relapsed advanced lymphomas. A phase II study. Cancer Chemother Pharmacol 1, 175-177
115. 115 Laubenstein LJ, Krigel RL, Hymes KB, Muggia FM (1983) Proc Am Soc Clin Onc 2, 228
116. 116 Ohyama S, Yonemura Y, Tugawa K, Kimura H, Kosaka T, Miyazaki I, Endo Y, Tanaka M, Sasaki T (1991) Application of anti-P-105 monoclonal antibody to analysis of mode of action of antitumor agents. Can To Kagaku Rhyoho 18, 1273-1278, (Chem Abstr 116, 50710r)
117. 116 Ohyama S, Yonemura Y, Tugawa K, Kimura H, Kosaka T, Miyazaki I, Endo Y, Tanaka M, Sasaki T (1991) Application of anti-P-105 monoclonal antibody to analysis of mode of action of antitumor agents. Can To Kagaku Rhyoho 18, 1273-1278, (Chem Abstr 116, 50710r)
118. 117 Yamamoto D, Ohishi H, Kozawa M, Inamori Y, Ishida T, Inoue M (1988) Study on conformations-biological activities relationships for Podophyllotoxin analogs based on crystal structure of desoxypodophyllotoxin (Anthricin). Chem Pharm Bull 36, 3239-3247
119. 118 Long BH, Casazza AM (1994) Structure-activity relationships of VP-16 analogues. Cancer Chemother Pharmacol 34 (suppl), S26-S31
120. 119 Dombernofsky P, Nissen N (1973) Schedule dependency of the antileukaemic activity of the podophyllotoxin-derivative VP-16-213 in L1210 leukaemia. Acta Pathol Microbiol Scand (A) 81, 715-724
121. 120 Roca J (1995) The mechanism of DNA topoisomerases. Trends Biol Sci 20, 156-160
122. 121 Joel S (1996) Antitumor treatment. The clinical pharmacology of etoposide: an update. Cancer Treatment Rev 22, 179-221
123. 122 Pommier Y (1993) DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemother Pharmacol 32, 103-108
124. 123 Lock RB, Hill BT (1988) Differential paterns of anti-tumor drug responses and mechanisms of resistance in a series of independently-derived VP-16 resistant human tumor cell lines. Int J Cancer 42, 373
125. 124 Pui CH, Relling M, Rivera G (1995) Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukaemia 9, 1990-1996
126. 125 Anzai H, Frost P, Abbruzzese JL (1992) Synergistic cytotoxicity with combined inhibition of topoisomerase I and II. Proc Am Assoc Cancer Res 33, 2573
127. 126 Schacter LP, Igwemezie LN, Seyedsadr M (1994) Clinical and pharmacokinetic over view of parenteral etoposide phosphate. Cancer Chemother Pharmacol 34 (suppl), S58-S63
128. 127 Budman DR (1996) Early studies of etoposide phosphate, a water-soluble prodrug. Sem Onc 23, 8-14
129. 128 Saito H, Yoshikawa H, Nishimura Y, Kondo S, Takeuchi T, Umezawa H (1986) Studies on lignan lactone antitumor agents II. Synthesis of N-alkylamino-and 2,6-dideoxy-2-aminoglycosidic lignan variants related to podophyllotoxin. Chem Pharm Bull 34, 3741-3746
130. 129 Hanauske AR, Wüster KC, Depenbrock H, Peter R, Block T, Vogelsang H, Rotter M, Burk K, Fröhlich A, Rastetter J (1994) Preclinical activity of NK 611, a new podophyllotoxin derivative, against clonogenic tumor cells. Proc Am Assoc Cancer Res 35, 2388
131. 130 Pagani O, Zucchetti M, Sessa C, De Fusco M, Kaeser-Fröhlich A, Hanauske A, Cavalli F (1996) Clinical and pharmacokinetic study of oral NK 611, a new podophyllotoxin derivative. Cancer Chemother Pharmacol 38, 541-547
132. 131 Lee KH, Imakura Y, Haruna M, Beers SA, Thurston LS, Dai HJ, Chen CH (1989) Antitumor agents 107. New cytotoxic 4-alkylamino analogues of 4′-demethylepipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Natl Prod 52, 606-613
133. 132 Lee KH, Beers SA, Mori M, Wang ZQ, Kuo YH, Li L, Liu SY, Chang J Y, Han FS, Cheng YC (1990) Antitumor agents 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4′-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II. J Med Chem 33, 1364-1368
134. 133 Wang ZQ, Kuo YH, Schnur D, Bowen JP, Liu SY, Han FS, Chang JY, Cheng YC, Lee KH (1990) Antitumor agents 113. New 4-′-Arylamino derivatives of 4′-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human topoisornerase II. J Med Chem 33, 2660-2666
135. 134 Zhang YL, Guo X, Cheng YC, Lee KH (1994) Antitumor agents 148. Synthesis and biological evaluation of novel 4β-amino derivatives of etoposide with better pharmacological profiles. J Med Chem 37, 446-452
136. 135 Anyanwutaku IO, Guo X, Cheng YC, Ji Z, Lee KH, Cheng YC (1996) Activities of novel non glycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells. Mol Pharmacol 49, 721-726
137. 136 Cho SJ, Kashiwada Y, Bastow KF, Cheng YC, Lee KH (1996) Antitumor agents 164. Podophenazine, 2″,3″dichloropodophenazine, benzopodophenazine, and their 4β-p-nitroaniline derivatives as novel DNA topoisomerase II inhibitors. J Med Chem 39, 1396-1402
138. 137 Leteurtre F, Madalengoitia J, Orr A, Cuzi TJ, Lehnert E, MacDonald T, Pommier Y (1992) Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin. Cancer Res 52, 4478-4483
139. 138 Tomioka K, Kubuta Y, Koga K (1989) Synthesis and antitumor activity of podophyllotoxin aza-analogues. Tetrahedron Lett 30, 2953-2954
140. 139 Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E, Pommier Y (1993) Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem Pharmacol 45, 2449-2456
141. 140 Eymin B, Solary E, Chevillard S, Dubrez L, Goldwasser F, Duchamp O, Genne P, Leteurtre F, Pommier Y (1995) Cellular pharmacology of azatoxins (topoisomerase II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. Int J Cancer 63, 268-275
142. 141 Terada T, Fujimoto K, Nomura M, Yamashita J, Wierzba K, Yamazaki R, Shibata J, Sugimoto Y, Yamada Y, Kobunai T, Takeda S, Minami Y, Yoshida K, Yamaguchi H (1993) Antitumor agents 3. Synthesis and biological activity of 4β-alkyl derivatives containing hydroxy, amino, and amtdo groups of 4′-O-demethyl-4-deoxypodophyllotoxin as antitumor agents. J Med Chem 36, 1689-1699
143. 142 Kobunai T, Saito H, Yoshida M, Toko T, Takeda S, Unemi N (1994) In vitro and in vivo antitumor activity against lung cancer of TOP-53, a novel podophyllotoxin derivative. Proc Am Assoc Cancer Res 35 Abst 2154
144. 143 Kobunai T, Saito H, Yoshida M, Utsugi T, Terada T, Yamada Y (1996) Antitumor activity of TOP-53, a novel podophyllotoxin derivative. Proc Am Assoc Cancer Res 37, Abst 22914
145. 144 TOP 53. Drugs of the Future (1996) 21, 1136
146. 145 Utsugi T, Shibata J, Sugimoto Y, Aoyagi K, Wierzba K, Kobunai T, Terada T, Oh-hara T, Tsuruo T, Yamada Y (1996) Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res 56, 2809-2814
147. 146 Allevi P, Anastasia M, Ciuffreda P (1993) The first synthesis of the N-glucosyl analogue of the antitumor agent etoposide. Tetrahedron Lett 34, 7313-7316
148. 147 Allevi P, Anastasia M, Ciuffreda P (1991) A short and simple synthesis of the thioglucose analogue of the antitumor agent etoposide. Tetrahedron Lett 32, 6927-6930
149. 148 Hitotsuyanagi Y, IchiharaY, Takeya K, Itokawa H (1994) Synthesis of 4-oxa-2-azapodophyllotoxin, a novel analog of the antitumor lignan podophyllotoxin. Tetrahedron Lett 35, 9401-9402
150. 149 Hitotsuyanagi Y, Naka Y, Yamagami K, Fujii A, Tahara T (1995) Synthesis of 2,4-diaza-4-deoxypodophyllotoxin, a new analogue of podophyllotoxin possessing antitumour activity. J Chem Soc Chem Comm 49-50
151. 150 Miguel Del Corral JM, Gordaliza M, Castro MA, Lopez JM, San Feliciano A (1995) Methyl ethers of podophyllotoxin-related cyclo-lignans. J Natl Prod 58, 870-877
152. 151 Wang YG, Pan JL, Chen YZ (1996) Synthesis and antitumor activity of new derivatives of podophyllotoxin. Chin Chem Lett 1, 987-988
153. 152 Berger JM, Gamblin SJ, Harrison SC, Wang JC (1996) Structure and mechanism of DNA topoisomerase II. Nature 379, 225-232
154. 153 Pommier Y (1997) DNA Topoisomerase II inhibitors. In: Cancer therapeutics: Experimental and Clinical agents (Teicher BA, ed) Humana Press, Totowa, New Jersey, 153-174